Vion (formerly Oncorx) interesting play on Gene Therapy Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vion (formerly Oncorx) interesting play on Gene Therapy

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: buffalodon2003	10/12/2007 6:15:39 PM
	Read Replies (1) of 370

I concur that Vion is making a slight consistent move (except for today). I'm in for the long haul with avg share of $1.20. Unfortunately, Vion does not have a varied active pipeline presently and simply, the next shoe to drop would in all probability be the news on Cloretazine. Hopefully, the Phase II stand alone trial will bring the desired results and remove the ARA-C problems in Phase III. I sent an email to Vion about two weeks ago because I found it difficult to understand the wording in the SEC releases (2) on 9/30/07. Howard Johnson was kind enough to return call. Apparently, the releases dealt with the stock option plans (i.e. authorizing shares etc.). The legal run-on sentences in these SEC releases are very difficult to understand.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next